Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130734 | 0.88 | KLK7 (0.73) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130650 | 0.85 | SMN1; SMN2 (0.80) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130740 | 0.85 | SMN1; SMN2 (0.70) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130736 | 0.85 | MAPT (0.78) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130733 | 0.84 | SMN1; SMN2 (0.79) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130648 | 0.83 | SMN1; SMN2 (0.77) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130651 | 0.82 | MAPT (0.81) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL11887745 | 0.81 | POLB (0.78) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130752 | 0.81 | SMN1; SMN2 (0.74) | KLK7SMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL17130742 | 0.81 | SMN1; SMN2 (0.70) | KLK7SMN1; SMN2MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179166-A1 | SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE | VIROCARB INC (CA) | 2018-06-28 | — | — | US | disclosed |
| WO-2015143535-A1 | SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE | VIROCARB INC. (CA) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179166-A1 | SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE | CD4, HAVCR2, CCR5 | KLK7 1959/4885SMN1; SMN2 4801/4885MAPT 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.